Other grades of this product :
| Carbimazole Basic information |
| Carbimazole Chemical Properties |
| Melting point | 124°C | | Boiling point | 240.4±23.0 °C(Predicted) | | density | 1.2900 (rough estimate) | | refractive index | 1.5400 (estimate) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO: soluble5mg/mL, clear (warmed) | | form | powder | | pka | -1.70±0.20(Predicted) | | color | white to beige | | Water Solubility | Soluble in water, ethanol, chloroform and acetone. Sightly soluble in water. | | Sensitive | Light Sensitive | | Merck | 14,1798 | | BRN | 144339 | | InChIKey | CFOYWRHIYXMDOT-UHFFFAOYSA-N | | CAS DataBase Reference | 22232-54-8(CAS DataBase Reference) | | NIST Chemistry Reference | Carbimazole(22232-54-8) |
| Provider | Language |
|
ALFA
| English |
| Carbimazole Usage And Synthesis |
| Chemical Properties | White Solid | | Originator | Carbimazol,Cid Co. | | Uses | Carbimazole, a prodrug of Methimazole (M260300), is used in the treatment of hyperthyroidism. | | Uses | Thionamide antithyroid drug. | | Uses | Ethyl 3-methyl-2-thionoimidazoline-1-carboxylate is used as thyroid inhibitor. | | Definition | ChEBI: A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism. | | Manufacturing Process | 0.1 mol of 1-methyl-2-mercaptoglyoxaline is dissolved in the minimum
quantity of pyridine at 0°C 0.1 mol of ethyl chloroformate is added drop wise
with stirring. More pyridine is added, if necessary, to keep the mixture semi-fluid. The sludge is then placed in an ice bath for 30 minutes. The crystals are
filtered off and washed firstly with a little ethanol and secondly with ethanol
and water. The non-basic desired ethyl 3-methyl-2-thioimidazoline-1-
carboxylate is the colourless needles having a melting point of 122°-123°C. | | Therapeutic Function | Thyroid inhibitor | | Clinical Use | Treatment of hyperthyroidism | | Synthesis | Carbimazole, the ethyl ester of 3-methyl-2-thioimidazolin-1-carboxylic acid
(25.2.7), is synthesized by a simultaneous reaction of ethylenacetal of bromoacetaldehyde
with methylamine and potassium isocyanate, forming 3-methyl-2-imidazolthione (25.2.6),
which is further acylated at the nitrogen atom by ethyl chloroformiate, giving the desired
product (25.2.7). | | Veterinary Drugs and Treatments | Carbimazole (a pro-drug of methimazole) or methimazole are
considered by most clinicians to be the agents of choice when using
drugs to treat feline hyperthyroidism. Propylthiouracil has significantly higher incidences of adverse reactions when compared to
methimazole.
Methimazole and therefore, carbimazole, may be useful for the
prophylactic prevention of cisplatin-induced nephrotoxicity in dogs. | | Drug interactions | Potentially hazardous interactions with other drugs
None known | | Metabolism | Carbimazole is rapidly metabolised to thiamazole,
which is concentrated in the thyroid gland. Over 90%
of orally administered carbimazole is excreted in the
urine as thiamazole or its metabolites. The remainder
appears in faeces. There is 10% enterohepatic circulation.
Thiamazole is metabolised, probably by the liver,
and excreted in the urine. Less than 12% of a dose of
thiamazole may be excreted as unchanged drug |
| Carbimazole Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye